Turn off MathJax
Article Contents
Xiaoyu Liu, Huihan Wang. Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease[J]. Blood&Genomics. doi: 10.46701/BG.2023022022037
Citation: Xiaoyu Liu, Huihan Wang. Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease[J]. Blood&Genomics. doi: 10.46701/BG.2023022022037

Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease

doi: 10.46701/BG.2023022022037
More Information
  • Corresponding author: Huihan Wang, Department of Hematology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Shenyang, Liaoning 110035, China. E-mail: wanghh@sj-hospital.org
  • Received Date: 2022-12-14
  • Rev Recd Date: 2023-03-05
  • Accepted Date: 2023-03-30
  • Available Online: 2023-06-01
  • Castleman disease (CD) is a rare and heterogeneous disease whose treatment options and prognosis vary with clinical types. Multicentric Castleman disease (MCD) is characterized by poor prognosis, and effective treatment options are still being explored. This study aimed to determine whether the E-COD (E: etoposide 50 mg/m2/d, d1–3; C: phosphoramide 750 mg/m2, d1, d3; O: vincristine 2 mg, d1; D: dexamethasone 10 mg/d, d1–5) regimen is effective in treating human herpesvirus-8 (HHV-8)-negative MCD. A group of patients diagnosed with MCD at Shengjing Hospital of China Medical University were treated with E-COD regimen. The effectiveness evaluation was conducted after four treatment cycles and follow-up for survival. A total of 101 patients were included in this study from January 2003 to December 2021, of whom 29 patients had HHV-8 negative MCD subtype. Seven HHV-8 negative MCD patients received four courses of E-COD chemotherapy. The complete response, partial response, and stable disease were 14.3%, 71.4%, and 14.3%, respectively. The follow-up ended on June 1, 2021. Two patients died, and five patients survived, with a survival period ranging from 2 to 11 years. This study suggests that the E-COD regimen is a safe, efficient, and affordable therapy option for HHV-8 negative MCD patients.


  • loading
  • [1]
    Yu L, Shi M, Cai Q, et al. A novel predictive model for idiopathic multicentric Castleman disease: the internatiman disease consortium study[J]. Oncologist, 2020, 25(11): 963−973. doi: 10.1634/theoncologist.2019-0986
    van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease[J]. Blood Adv, 2020, 4(23): 6039−6050. doi: 10.1182/bloodadvances.2020003334
    van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20): 2115−2124. doi: 10.1182/blood-2018-07-862334
    Frizzera G. Castleman's disease and related disorders[J]. Semin Diagn Pathol, 1988, 5(4): 346−364
    Zhang X, Rao H, Xu X, et al. Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients[J]. Cancer Sci, 2018, 109(1): 199−206. doi: 10.1111/cas.13439
    Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor[J]. Br J Haematol, 2015, 169(6): 834−842. doi: 10.1111/bjh.13378
    Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease[J]. Blood, 2017, 129(12): 1658−1668. doi: 10.1182/blood-2016-11-748855
    Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133(16): 1720−1728. doi: 10.1182/blood-2018-11-884577
    Zou WY, Lan HX, Su C, et, al. Retrospective study of Castleman's disease: a report of fourteen cases and review of the literature[J]. Chin J Clin Oncol (in Chinese), 2007, 34(22): 195−200.
    Murphy C, Hawkes E, Chionh F, et al. Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab, and liposomal doxorubicin in an HHV8-positive, HIV-negative patient[J]. J Clin Pharm Ther, 2017, 42(1): 111−114. doi: 10.1111/jcpt.12472
    Dispenzieri A. Castleman disease[J]. Cancer Treat Res, 2008, 142: 293−330. doi: 10.1007/978-0-387-73744-7_13
    van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double- blind, placebo controlled trial[J]. Lancet Oncol, 2014, 15(9): 966−974. doi: 10.1016/S1470-2045(14)70319-5
    Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment[J]. Blood, 2004, 103(5): 163−634. doi: 10.1182/blood-2003-05-1721
    Song Y, Wang J, Wang Y, et al. Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis[J]. Cancer Biol Ther, 2021, 22(10–12): 598−606. doi: 10.1080/15384047.2021.1996139
    Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease[J]. Blood, 2020, 135(16): 1353−1364. doi: 10.1182/blood.2019000931
    Zhang L, Li Z, Cao X, et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor[J]. Sci Rep, 2016, 6: 23831. doi: 10.1038/srep23831
    Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics[J]. Cancer Chemother Pharmacol, 1994, 34: Suppl: S69−75. doi: 10.1007/BF00684867
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索


    Article Metrics

    Article views (178) PDF downloads(2) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint